Edition:
United Kingdom

ARCA Biopharma Inc (ABIO.OQ)

ABIO.OQ on NASDAQ Stock Exchange Capital Market

0.56USD
23 Apr 2018
Change (% chg)

$0.00 (+0.36%)
Prev Close
$0.55
Open
$0.58
Day's High
$0.58
Day's Low
$0.55
Volume
56,827
Avg. Vol
123,524
52-wk High
$2.75
52-wk Low
$0.45

Latest Key Developments (Source: Significant Developments)

ARCA Biopharma Anticipates Meeting With FDA In Q2
Monday, 26 Feb 2018 

Feb 26 (Reuters) - ARCA Biopharma Inc ::ARCA BIOPHARMA REPORTS TOPLINE PHASE 2B RESULTS FOR GENETIC-AF CLINICAL TRIAL.ARCA BIOPHARMA INC - ‍ANTICIPATES MEETING WITH U.S. FDA IN Q2 OF 2018 TO REVIEW PHASE 2 DATA AND PHASE 3 DEVELOPMENT PLAN​.ARCA BIOPHARMA INC - ‍GENCARO DEMONSTRATES COMPARABLE EFFICACY TO ACTIVE CONTROL AND TREND FOR POTENTIAL GENCARO SUPERIORITY IN US PATIENT COHORT​.ARCA BIOPHARMA INC - ‍SAFETY DATA INDICATED THAT GENCARO WAS GENERALLY SAFE AND WELL-TOLERATED IN AF/HEART FAILURE POPULATION​.ARCA BIOPHARMA INC - ‍THREE PATIENTS DIED IN LONG-TERM TREATMENT EXTENSION PERIOD AFTER RECEIVING GENCARO FOR MORE THAN A YEAR​.ARCA BIOPHARMA INC - ‍ENDED 2017 WITH CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES TOTALING $11.8 MILLION​.ARCA BIOPHARMA - ‍BELIEVES FUNDS, WITH NET PROCEEDS OF ABOUT $3.4 MILLION RAISED IN JAN WILL BE SUFFICIENT TO FUND OPERATIONS THROUGH END OF 2018​.  Full Article

Arca Biopharma announces issuance of European patent on cardiovascular disease treatment methods
Thursday, 16 Nov 2017 

Nov 16 (Reuters) - Arca Biopharma Inc :Arca Biopharma announces issuance of European patent for treating cardiovascular diseases and conditions with a new chemical entity utilizing genetic targeting.Arca Biopharma- believes current cash, cash equivalents,marketable securities will be sufficient to fund its operations through end of Q2 of 2018​.  Full Article

ARCA Biopharma announces third quarter financial results
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Arca Biopharma Inc :ARCA Biopharma announces third quarter 2017 financial results and provides business update.Q3 loss per share $0.39.ARCA Biopharma Inc - anticipate reporting top-line data for Genetic-AF clinical trial​ late in Q1 of 2018.ARCA Biopharma Inc - ‍expects research and development expenses in 2017 to be higher than 2016​.  Full Article

Arca Biopharma Inc says‍ it entered into amendment no. 1 to its capital on demand sales agreement
Monday, 21 Aug 2017 

Aug 21 (Reuters) - Arca Biopharma Inc ::Arca Biopharma Inc says‍ on Aug 21, co entered into amendment no. 1 to its capital on demand sales agreement, dated as of January 11, 2017 .Arca Biopharma-‍amendment increased maximum offering value of shares of co's stock which co may issue, sell from time to time under sales agreement​.Amendment ‍increased maximum aggregate offering value of shares by approximately $2.9 million, from $7.3 million to $10.2 million ​.  Full Article

ARCA Biopharma to share top-line results in Q1 next year for GENETIC-AF trial​
Wednesday, 9 Aug 2017 

Aug 9 (Reuters) - ARCA Biopharma Inc ::ARCA Biopharma announces GENETIC-AF data and safety monitoring board recommendation to complete Phase 2B GENETIC-AF clinical trial based on efficacy and safety data in phase 2b interim analysis.ARCA Biopharma Inc - ‍Gencaro development program has been granted fast track designation by U.S. FDA​.ARCA Biopharma Inc - ‍look forward to sharing top-line trial results late in Q1 of next year for GENETIC-AF trial​.  Full Article

Arca Biopharma Q2 loss per share $0.59
Thursday, 3 Aug 2017 

Aug 3 (Reuters) - Arca Biopharma Inc :Arca Biopharma announces second quarter 2017 financial results and provides business update.Q2 loss per share $0.59.  Full Article

ARCA Biopharma Q1 loss per share $0.48
Monday, 15 May 2017 

May 15 (Reuters) - Arca Biopharma Inc :Arca biopharma announces first quarter 2017 financial results and provides business update.Q1 loss per share $0.48.Arca biopharma - current cash, cash equivalents and marketable securities will be sufficient to fund operations, at its projected cost structure, through end of 2017.Arca biopharma inc - cash, cash equivalents and marketable securities totaled $19.2 million as of march 31, 2017, compared to $23.5 million as of december 31, 2016.Arca biopharma-expects g&a expenses in 2017 to be higher than in 2016 as it increases administrative activities to support genetic-af clinical trial.  Full Article

Arca Biopharma announces 200th patient randomized into the genetic-AF phase 2b/3 clinical trial
Wednesday, 26 Apr 2017 

April 26 (Reuters) - Arca Biopharma Inc :Arca Biopharma announces 200th patient randomized into the genetic-AF seamless design phase 2b/3 clinical trial.Outcome of phase 2B interim efficacy analysis anticipated in September 2017.  Full Article

Arca Biopharma Inc files for mixed shelf of up to $75 mln
Tuesday, 25 Apr 2017 

April 25 (Reuters) - Arca Biopharma Inc : :Arca Biopharma Inc files for mixed shelf of up to $75 million .  Full Article

ARCA Biopharma 2016 net loss $16.4 mln, or $1.81 per share
Tuesday, 21 Mar 2017 

ARCA Biopharma Inc : Arca biopharma announces fiscal year 2016 financial results and provides business update . Arca biopharma inc - net loss was $16.4 million, or $1.81 per share, for 2016 compared to $11.4 million, or $1.82 per share, for 2015 .Arca biopharma - believes current cash, cash equivalents, to be sufficient to fund operations, at projected cost structure, through end of 2017.  Full Article

BRIEF-Arca Biopharma And Medtronic Extend Gencaro Clinical Trial Collaboration Agreement

* ARCA BIOPHARMA AND MEDTRONIC EXTEND GENCARO CLINICAL TRIAL COLLABORATION AGREEMENT